The present invention relates to methods of generating and expanding hitman embryonic stem eel! derived mesenchymal-like stem/siromal cells. These hES-MSCs are characterized at least in part by the low level of expression of IL-6. These cells are useful for the prevention and treatment of T cell related autoimmune disease, especially multiple sclerosis, as well as for delivering agents across the blood-brain barrier and the blood-spinal cord barrier. Also provided is a method of selecting clinical grade hES-MSC and a method of modifying MSC to produced a MSC with specific biomarker profile. The modified MSC are useful for treatment of various diseases.

The present invention relates to inter alia, methods for the generation and maintenance of Mesoderm-derived ISL1+ Multipotent Progenitors (IMPs), the production of a number of pluripotent cells including and epicardial pluripotent cells (EPCs) and using these cells to produce endothelial cells, cardiomyocytes, smooth muscle cells, vascular cells and other cells and related methods as otherwise disclosed herein. The invention also relates to compositions comprising a population of cells.

Use of endothelial progenitor cells in the manufacture of a medicament for rejuvenating neovascularization capacity, ameliorating aging features, preventing aging, extending lifespan, and/or treating progeria and/or age-related diseases. A method for rejuvenating neovascularization capacity, ameliorating aging features, preventing aging, extending lifespan, and/or treating progeria and/or age-related diseases, includes: administering a pharmaceutically effective amount of EPCs to a subject in need thereof.

An isolated biological stem cell or a set of biological stem cells that include human mesenchymal stem cell line 120816CT, deposited under ATCC Accession number PTA-124321, and differentiated into at least one type of cell selected from the group: neural stem cells, nephron progenitor cells, cardiomyocytes, neurons, glial cells, and vascular endothelial cells. The neurons comprise cholinergic neurons or dopaminergic neurons. A method of treating at least one human physical condition is also disclosed. The method includes injecting a patient with stem cell line 120816 CT to treat osteoarthritis, tendonitis, herniated disc, ligament damage, acute and chronic kidney disease and injury, Parkinson's disease, traumatic brain injury, Alzheimer's disease, amyotrophic lateral sclerosis, spinal cord injury, other skeletal muscular disorders, Lupus erythematosus, multiple sclerosis, cardiovascular disease, Graft-versus host disease, liver dysfunction or diseases, Type 1 and Type 2 diabetes, myocardial ischemia, heart failure, coronary artery disease, and other disorders characterized by inflammation.

A method for producing a population of cells, enriched for non-adherent endothelial progenitor cells (EPCs), the method comprising culturing an EPC containing population of cells in the presence of interleukin-3 (IL-3), such that a population of cells enriched for non-adherent EPCs is produced.

Methods for obtaining multipotent Apelin receptor-positive lateral plate mesoderm cells, mesenchymal stem cells, and mesangioblasts under serum-free conditions are disclosed.

Thus, provided herein are pericyte progenitor cells (e.g., isolated pericyte progenitor cells), methods for generating pericyte progenitors in clinically relevant numbers for various applications applying macromolecular crowding during cell culture, and methods of using the pericyte progenitor cells.

Platelet lysate compositions and cell culture media compositions for maintaining and/or growing mammalian cells, such as mammalian endothelial cells (ECs) and mammalian endothelial progenitor cells (EPCs), in particular human ECs (huECs) and human EPCs (huEPCs), such as primary huECs and primary huEPCs, are provided. The cell culture media compositions contain a basal medium, a platelet lysate and, optionally, one or more exogenously added growth factors. Also provided are methods for making and using such cell culture media compositions to grow and/or maintain ECs and EPCs, including huECs and huEPCs, as well as cell culture vessels, dishes, plates, and/or flasks pretreated with the cell culture media compositions.

The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and method sof treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.

Provided herein are human arterial endothelial cell-seeded polymeric vascular grafts suitable for replacing or bypassing natural blood vessels and exhibiting increased long term patency rates and reduced leukocyte adhesion relative to grafts comprising venous endothelial cells. Methods for generating the human arterial endothelial cell-seeded vascular grafts and therapeutic uses of the same are also described.